Grass pollen allergy vaccine - Circassia

Drug Profile

Grass pollen allergy vaccine - Circassia

Alternative Names: Grass-SPIRE; Grass-Synthetic Peptide Immuno-Regulatory Epitope; ToleroMune Grass

Latest Information Update: 08 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Circassia
  • Class Allergens; Allergy immunotherapies; Antiallergics; Peptide vaccines; Peptides; Plant allergy immunotherapies
  • Mechanism of Action Immunosuppressants; T lymphocyte modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Seasonal allergic rhinitis

Most Recent Events

  • 21 Jun 2016 Circassia terminates a phase II/III trial in Seasonal allergic rhinitis (In adolescents, In adults) in USA due to the availability of results from another study (NCT02795273)
  • 24 Jun 2015 Phase-II development is ongoing in Canada
  • 31 Dec 2014 Circassia initiates TG002 and TG004 phase II trials for Seasonal allergic rhinitis in Canada prior to December 2014
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top